Triazolone-Functionalized Magnetic Nanoparticles for Hemoglobin Purification and Proteomics-Driven Biomarker Discovery in Diabetic Blood.

Journal: Analytical chemistry
Published Date:

Abstract

Hemoglobin, particularly glycated hemoglobin, serves as the gold standard for diagnosing diabetes in clinical settings. In this study, a triazolinone derivative, 3-chloromethyl-1,2,4-triazol-5-one (CMTO), was conjugated to polyethylenimide-modified magnetic nanoparticles via an amination reaction, resulting in the formation of a novel composite material, CMTO@FeO-NH. Molecular simulations revealed that the carbonyl group of CMTO underwent tautomerization to an enol form under neutral pH conditions. The enol form established hydrogen bonds with phenylalanine residues in hemoglobin, while the triazole ring interacted with the hemoglobin β-subunit through π-π interactions. These interactions significantly enhanced the performance of CMTO@FeO-NH in the effective separation and purification of hemoglobin. Specifically, 1.0 mg of CMTO@ FeO-NH successfully adsorbed hemoglobin from 0.5 mL of a 100 μg mL hemoglobin solution, with an excellent adsorption efficiency of 93.8% in just 45 min. The adsorption process was found to follow the Langmuir model with a theoretical adsorption capacity of 344.83 mg g. Furthermore, with a 91.2% elution efficiency, the adsorbed hemoglobin could be efficiently eluted using a 100 mmol L imidazole solution. After five cycles, the material retained 88.1% of its initial adsorption efficiency. Encouraged by its hemoglobin adsorption efficiency, the composite material was applied to selectively separate hemoglobin from human whole blood. Protein sequencing identified 1114 proteins in this process, with 252 differential proteins found between diabetic and healthy individuals. Pathway analysis and protein-protein interaction (PPI) networks identified 12 potential diabetic biomarkers.

Authors

  • Xinze Wu
    School of Pharmacy, Shenyang Medical College, Shenyang 110034, People's Republic of China.
  • Lingxi Zhang
    School of Pharmacy, Shenyang Medical College, Shenyang 110034, People's Republic of China.
  • Tian Luan
    School of Pharmacy, Shenyang Medical College, Shenyang 110034, People's Republic of China.
  • Ying Wang
    Key Laboratory of Macromolecular Science of Shaanxi Province, School of Chemistry & Chemical Engineering, Shaanxi Normal University, Xi'an, Shaanxi 710062, China.
  • Xiangyu Liu
    School of Pharmacy, Shenyang Medical College, Shenyang 110034, People's Republic of China.
  • Mingsheng Zhou
    Shenyang Key Laboratory of Vascular Biology, Science and Experiment Center, Shenyang Medical College, Shenyang 110034, People's Republic of China.
  • Fu Ren
    Shenyang Key Laboratory for Phenomics, Liaoning Province Key Laboratory for Phenomics of Human Ethnic Specificity and Critical Illness, Shenyang Medical College, Shenyang 110034, People's Republic of China.
  • Qing Chen
    Institute of Toxicology, Facutly of Military Preventive Medicine, Army Medical University (Third Military Medical University), Chongqing 400038, China.
  • Xifan Mei
    Liaoning Vocational College of Medicine, Shenyang 110101, People's Republic of China.
  • Xuwei Chen
    Research Center for Analytical Sciences, Department of Chemistry, College of Sciences, Northeastern University, Shenyang 110819, People's Republic of China.
  • Jianhua Wang
    Gene Engineering Laboratory, Feed Research Institute, Chinese Academy of Agricultural Sciences, Beijing 100081, China.

Keywords

No keywords available for this article.